日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

An intriguing journey into the hereditary syndromes predisposing to endometrial cancer: more than believed

一段引人入胜的探索之旅,揭示了导致子宫内膜癌的遗传综合征:远超人们的想象。

Fanale, Daniele; Magrin, Luigi; Corsini, Lidia Rita; Pedone, Erika; Brando, Chiara; Bazan Russo, Tancredi Didier; Ferraro, Pietro; Carobene, Karen; Cipolla, Elga Adriana; Colletta, Giovanni; Puglisi, Mattia; Galvano, Antonio; Vieni, Salvatore; Pantuso, Gianni; Giannone, Antonino Giulio; Badalamenti, Giuseppe; Incorvaia, Lorena; Russo, Antonio; Bazan, Viviana

Liquid biopsy in Oncology: Results of a Delphi consensus study endorsed by the AIOM-SIAPEC/IAP-SIBioC-SIF Italian scientific societies

肿瘤学中的液体活检:一项由意大利科学协会AIOM-SIAPEC/IAP-SIBioC-SIF认可的德尔菲共识研究结果

Gristina, Valerio; Malapelle, Umberto; Daniele, Gennaro; Iannantuono, Giovanni Maria; Bazan Russo, Tancredi Didier; Berardi, Rossana; Beretta, Giordano Domenico; Capoluongo, Ettore Domenico; Ciaccio, Marcello; Danesi, Romano; Del Re, Marzia; Fassan, Matteo; Giuffrè, Giuseppe; Gori, Stefania; Incorvaia, Lorena; Marchetti, Antonio; Normanno, Nicola; Pinto, Carmine; Santini, Daniele; Sartore Bianchi, Andrea; Silvestris, Nicola; Tagliaferri, Pierosandro; Troncone, Giancarlo; Di Maio, Massimo; Perrone, Francesco; Galvano, Antonio; Rolfo, Christian; Russo, Antonio

18F-Fluorodeoxyglucose Uptake in PDGFRA-Mutant Gastrointestinal Stromal Tumors

PDGFRA突变型胃肠道间质瘤对18F-氟代脱氧葡萄糖的摄取

Nigro, Maria Concetta; Marchetti, Andrea; Fumagalli, Elena Rosa; De Luca, Ida; Bertuzzi, Alexia Francesca; Grimaudo, Maria Susanna; Grignani, Giovanni; D'Ambrosio, Lorenzo; Merlini, Alessandra; Badalamenti, Giuseppe; Incorvaia, Lorena; Dimino, Alessandra; Gasperoni, Silvia; Vincenzi, Bruno; Fanti, Stefano; Di Federico, Alessandro; Campana, Davide; Pantaleo, Maria Abbondanza; Nannini, Margherita

BRCA functional domains associated with high risk of multiple primary tumors and domain-related sensitivity to olaparib: the Prometheus Study

BRCA功能域与多原发肿瘤高风险相关,且对奥拉帕尼具有结构域相关性敏感性:普罗米修斯研究

Incorvaia, L; Marchetti, C; Brando, C; Bazan Russo, T D; Bono, M; Perez, A; Congedo, L; Ergasti, R; Castellana, L; Insalaco, L; Contino, S; Gristina, V; Galvano, A; Fanale, D; Badalamenti, G; Russo, A; Scambia, G; Bazan, V

Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study

根据 BRCA1/2 突变类型和部位评估新诊断卵巢癌患者接受 PARP 抑制剂维持治疗的获益:一项多中心真实世界研究

Marchetti, C; Fagotti, A; Fruscio, R; Cassani, C; Incorvaia, L; Perri, M T; Sassu, C M; Camnasio, C A; Giudice, E; Minucci, A; Seca, M; Arbustini, E; Vertechy, L; De Bonis, M; Boccia, S M; Giannarelli, D; Salutari, V; Distefano, M; Ferrandina, M G; Nero, C; Musacchio, L; Russo, A; Scambia, G; Lorusso, D

Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study: Not all BRCA mutations are equal: functional context and mutation type as co-determinants of PARP inhibitor response

关于“根据BRCA1/2突变类型和部位评估PARP抑制剂维持治疗对新诊断卵巢癌患者的益处:一项多中心真实世界研究”的来信回复:并非所有BRCA突变都相同:功能背景和突变类型是PARP抑制剂疗效的共同决定因素

Marchetti, C; Fagotti, A; Fruscio, R; Cassani, C; Incorvaia, L; Perri, M T; Sassu, C M; Camnasio, C A; Giudice, E; Minucci, A; Seca, M; Arbustini, E; Vertechy, L; De Bonis, M; Boccia, S M; Giannarelli, D; Salutari, V; Distefano, M; Ferrandina, M G; Nero, C; Musacchio, L; Russo, A; Scambia, G; Lorusso, D

Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study

回复关于“根据BRCA1/2突变类型和部位评估PARP抑制剂维持治疗对新诊断卵巢癌患者的益处:一项多中心真实世界研究”的来信

Marchetti, C; Fagotti, A; Fruscio, R; Cassani, C; Incorvaia, L; Perri, M T; Sassu, C M; Camnasio, C A; Giudice, E; Minucci, A; Seca, M; Arbustini, E; Vertechy, L; De Bonis, M; Boccia, S M; Giannarelli, D; Salutari, V; Distefano, M; Ferrandina, M G; Nero, C; Musacchio, L; Russo, A; Scambia, G; Lorusso, D

First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study

一线免疫疗法联合方案或舒尼替尼治疗预后良好的转移性肾细胞癌:来自 ARON-1 研究的真实世界回顾性比较

Roviello, Giandomenico; Molina-Cerrillo, Javier; Massari, Francesco; Cerbone, Linda; Fiala, Ondrej; Fornarini, Giuseppe; Monteiro, Fernando Sabino Marques; Cattrini, Carlo; Landmesser, Johannes; Messina, Carlo; Zgura, Anca; Rebuzzi, Sara Elena; Soares, Andrey; Carrozza, Francesco; Ansari, Jawaher; Grillone, Francesco; Küronya, Zsófia; Incorvaia, Lorena; Bhuva, Dipen; Ortega, Cinzia; Nasso, Cecilia; Kanesvaran, Ravindran; Zampiva, Ilaria; Porta, Camillo; Buti, Sebastiano; Santoni, Matteo

On-treatment dynamics of circulating extracellular vesicles in the first-line setting of patients with advanced non-small cell lung cancer: the LEXOVE prospective study

晚期非小细胞肺癌患者一线治疗期间循环细胞外囊泡的动态变化:LEXOVE 前瞻性研究

Gristina, Valerio; Bazan, Viviana; Barraco, Nadia; Taverna, Simona; Manno, Mauro; Raccosta, Samuele; Carreca, Anna Paola; Bono, Marco; Bazan Russo, Tancredi Didier; Pepe, Francesco; Pisapia, Pasquale; Incorvaia, Lorena; Badalamenti, Giuseppe; Troncone, Giancarlo; Malapelle, Umberto; Santini, Daniele; Russo, Antonio; Galvano, Antonio

Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV Cohort

Enfortumab Vedotin 在铂类化疗和帕博利珠单抗治疗转移性尿路上皮癌后的疗效:ARON-2EV队列的多中心真实世界分析

Fiala, Ondrej; Grillone, Francesco; Fujita, Kazutoshi; Grande, Enrique; Giannatempo, Patrizia; Taha, Tarek; Myint, Zin W; Büttner, Thomas; de Liaño, Alfonso Gómez; Kanesvaran, Ravindran; Facchini, Gaetano; Yano, Akihiro; Formisano, Luigi; Poprach, Alexandr; Conteduca, Vincenza; Pirshtuk, Alina; Studentova, Hana; Kopecky, Jindrich; Sammarco, Enrico; Mota, Augusto; Incorvaia, Lorena; Nasso, Cecilia; Maffezzoli, Michele; Ghose, Aruni; Soares, Andrey; Buti, Sebastiano; Marques Monteiro, Fernando Sabino; Massari, Francesco; Gupta, Shilpa; Bellmunt, Joaquim; Banna, Giuseppe Luigi; Santoni, Matteo